Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Plus, why this drug may also be heart healthy.
A new study from Dr. Doug Melton’s team provides hope for the future of stem cell treatment in diabetes. But there’s still a long way to go.
Closed loop systems, stem cells, smart insulin, and more!
How safe and effective is Jardiance in people with type 1 diabetes?
Currently enrolling! How does the pill form of this drug class compare to injected GLP-1s?
Why the company decided against pursuing its type 2 GLP-1 drug Victoza to the FDA for use in type 1 diabetes.
My somewhat-impatient response to the recent New York Times article, “Some Older Patients Are Treated Not Wisely, but Too Much.”
Pivotal trial to start in early 2017. What does glucagon add to automated insulin delivery?
People with type 2 diabetes should contact their physicians if they notice new pain, sores, or infections on their legs or feet.
Results from the SCALE study show weight loss, delayed onset of type 2 diabetes, and report improved quality of life
Matchstick-sized device implanted under the skin every 6-12 months. New data in over 4,000 people demonstrates it is safe for heart health. Could it launch by late 2017?
Patients with high A1c levels could achieve greater blood glucose control from the start.
A six-month study of Diasome Pharmaceuticals’ HDV Insulin in Type 1 Diabetes
Public workshop scheduled at FDA for August 29, 2016. Get involved!
Use 4 mm needles, rotate injection sites, and more – why the little stuff matters
What are the implications for other injected GLP-1 agonist drugs?
Why Novo Nordisk and Sanofi’s combination drugs are potential gamechangers for type 2 diabetes.
less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide
Plus, Lilly invests $5 million! We talk to Dr. Ed Damiano to learn about the new Gen 3 version and upcoming studies.
LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...